DoMore Diagnostics achieves CE-IVD mark for Histotype Px® Colorectal, an AI algorithm that predict patient outcomes in colorectal cancer patients by analyzing standard histology images
Oslo, Norway - DoMore Diagnostics, a leader in cancer outcome prediction with pathology AI algorithms, today announced that it has achieved CE-IVD mark for the Histotype Px Colorectal, a deep learning algorithm that predict patient outcome based on analysis of digital histology images.
This is the first CE-marked product to utilize artificial intelligence to predict patient outcome based on advanced image analysis. Histotype Px Colorectal builds on the extensive research led by Institute for Cancer Genetics and Informatics at Oslo University Hospital, and the deep learning algorithm is trained on and developed with close to 100 million image tiles. The analysis is conducted on high resolution scans from standard H&E stained slides providing shorter turnaround times.
Every year close to 2 million patients worldwide are diagnosed with colorectal cancer, and despite decades of comprehensive research and large investments into gene sequencing, there is large medical need for better prognostic and predictive markers for patients with colorectal cancer. Many of these patients will suffer from unnecessary and harmful overtreatment while others may receive less intensive treatment than they need.
The results of an early version of the algorithm were first published in the prestigious journal The Lancet. During the last year, DoMore Diagnostics has improved the algorithm and developed a commercially available product. "With the Histotype Px Colorectal, clinicians and patients can receive patient risk information immediately after surgery, weeks to months faster than markers available today", Dr Tomas Nordheim Alme, MD said.
“We are very excited about this CE-mark as it enables clinical use across Europe. The product fits well within the existing hospital workflow and adds real value to the various digital pathology platforms available. This product makes so much sense for patients, healthcare providers and payers. With the simplicity and unmatched turnaround time we can provide physicians with additional valuable information to make the best treatment decisions for patients. We believe prognostic and predictive algorithms will unlock the full value of digital pathology” DoMore Diagnostics CEO and Co-founder Torbjørn Furuseth said.
For more information about the Histotype Px Colorectal, please contact contact@domorediagnostics.com.